Clinical Retrospective Evidence

Clinical Retrospective Evidence*

In a Phase II study, personalized Champions TumorGraft® data predicted patient outcomes1:

  • Phase II study in patients with pancreatic ductal adenocarcinoma
  • 26 patients were clinically treated with gemcitabine following pancreatectomy and tumor resection
  • 26 Champions TumorGraft PDX tumor models were treated with gemcitabine and assessed for responsiveness
  • Response rate to gemcitabine in the TGs (13 percent) was similar to that reported in the clinic

  • Trend for longer DFS in patients predicted sensitive by the Champions TumorGraft model
  • Disease-free survival was nearly fourfold in patients predicted to be sensitive to gemcitabine therapy per PDX model data vs. PDX model nonresponders (>800 vs. 206 days, P=0.08)

*Rubio-Viqueira B et al., Clin Cancer Res, 2006, 1;12:4652-61; Hidalgo M, ASCO GI, 2009

Learn More about Prospective Clinical Evidence >

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology